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Abstract
Background: Upon initial infection with mycobacteria, macrophages secrete multiple cytokines and chemokines,
including interleukin-6 (IL-6), IL-8 and tumor necrosis factor-a (TNF-a), to mediate host immune responses against
the pathogen. Mycobacteria also induce the production of IL-10 via PKR activation in primary human monocytes and
macrophages. As an anti-inflammatory cytokine, over-expression of IL-10 may contribute to mycobacterial evasion of
the host immunity. Radix Paeoniae Rubra (RPR, Chishao), a Chinese medicinal herb with potentials of anti-
inflammatory, hepatoprotective and neuroprotective effects, is used to treat tuberculosis. This study investigates the
immunoregulatory effects of RPR on primary human blood macrophages (PBMac) during mycobacterial infection.
Methods: The interaction of Bacillus Calmette-Guerin (BCG) with PBMac was used as an experimental model.
A series of procedures involving solvent extraction and fractionation were used to isolate bioactive constituents in
RPR. RPR-EA-S1, a fraction with potent immunoregulatory effects was obtained with a bioactivity guided
fractionation scheme. PBMac were treated with crude RPR extracts or RPR-EA-S1 before BCG stimulation. The
expression levels of IL-6, IL-8, IL-10 and TNF-a were measured by qPCR and ELISA. Western blotting was used to
determine the effects of RPR-EA-S1 on signaling kinases and transcriptional factors in the BCG-activated PBMac.
Results: In BCG-stimulated macrophages, crude RPR extracts and fraction RPR-EA-S1 specifically inhibited IL-10
production while enhanced IL-8 expression at both mRNA and protein levels without affecting the expressions of
IL-6 and TNF-a. Inhibition of BCG-induced IL-10 expression by RPR-EA-S1 occurred in a dose- and time-dependent
manner. RPR-EA-S1 did not affect the phosphorylation of cellular protein kinases including MAPK, Akt and GSK3b.
Instead, it suppressed the degradation of IBa in the cytoplasm and inhibited the translocation of transcription
factor NF-B1 p50 to the nucleus.
Conclusion: RPR crude extracts and its fraction RPR-EA-S1 inhibited anti-inflammatory cytokine IL-10 and enhanced
pro-inflammatory chemokine IL-8 expression in BCG-activated PBMac. The inhibitory effects of RPR-EA-S1 on IL-10
expression in BCG-activated PBMac may be due to the reduced nuclear translocation of NF-B1 p50.
Background
Tuberculosis (TB) remains a major cause of morbidity
and mortality worldwide as a result of Mycobacterium
tuberculosis (Mtb) infection. In 2008, an estimated 9.4
million new cases of TB and 1.3 million deaths were
recorded globally [1]. Although anti-TB drugs and
vaccines have been used for decades, the emergence of
multidrug-resistant TB (MDR-TB) and the co-infection
of Mtb and related mycobacteria with human immuno-
deficiency virus (HIV) pose new challenges to the treat-
ment of TB [1,2].
Upon Mtb infection, multiple immune cells including
macrophages/monocytes [3], dendritic cells (DCs) [4],
neutrophils [5], natural killer cells [6] and T cells [6] are
activated to mediate host defense against the pathogen.
Among these cell types, macrophages are the main
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immunocytes in initiating innate immunity against Mtb.
Macrophages are professional antigen presenting cells
that are important in bridging innate and adaptive
immunity [7]. Macrophages exert their direct anti-
microbial effects through phagocytosis [8], generation of
reactive oxygen intermediates (ROIs) and reactive nitro-
gen intermediates (RNIs) [9], autophagy [10], activation
of vitamin D pathway [11], apoptosis [12] and secretion
of cytokines and chemokines [13].
Specific cytokines and chemokines produced by macro-
phages during Mtb infection play important roles in reg-
ulating the host innate and adaptive immune responses
[13]. For example, tumor necrosis factor-a (TNF-a)
enhances the activity of macrophage to kill replicating
Mtb in synergy with interferon-g (IFN-g) [14] and contri-
butes to the formation of granuloma and prevention of
mycobacterial dissemination through decreased cell
migration [15]. Another key cytokine is interleukin-6
(IL-6), which is a pro-inflammatory cytokine that regu-
lates B and T cell activities and contributes to the initial
innate responses to Mtb [16].
IL-8, another important chemokine against Mtb, is pri-
marily secreted by monocytes and macrophages but also
produced by fibroblasts, keratinocytes, and lymphocytes
[17]. The induction of IL-8 can be stimulated by multiple
factors including pathogens, toxins and cytokines [18].
Previous studies have demonstrated the connection
between IL-8 production and Mtb infection. In clinical
studies, remarkably elevated levels of IL-8 were found in
tuberculous pleural exudate, bronchoalveolar lavage fluid,
cerebrospinal fluid and tuberculous granulomas [19]. In
contrast, decreased IL-8 secretion was observed in HIV-
infected patients with miliary TB, suggesting that the
absence of IL-8 induction is detrimental to restricting
Mtb dissemination [20]. Such important role of IL-8 was
illustrated in a previous study that upon Mtb infection
IL-8 attracted neutrophils and T lymphocytes to the
infection sites at an early stage, resulting in the formation
of granuloma [21].
Unlike the pro-inflammatory cytokines IL-6 and IL-8,
interleukin-10 (IL-10) is a key anti-inflammatory cyto-
kine produced by macrophages, Th1 cells [22], Th2 cells
[22], regulatory CD4+ T cells [23], CD8+ T cells [23],
DCs and B cells [24]. IL-10 mainly plays a negative role
in the regulation of immunity to prevent uncontrolled
responses to pathogens [25,26]. It inhibits the produc-
tion of pro-inflammatory cytokines, such as IFN-g,
IL-12, IL-18, IL-1 and TNF-a, by macrophages and DCs
[27]. Together with reduced induction of inducible nitric
oxide synthases (iNOS) and ROIs, IL-10 expression
results in reduced killing of intracellular pathogens by
macrophages [28]. IL-10 is also an inhibitor of antigen
presentation by macrophages and DCs through down-
regulation of MHCII expression [29-31]. In the event of
TB progression, over-expression of IL-10 results in a
higher mycobacterial burden and reactivation of pul-
monary TB [32]. Macrophages from IL-10 deficient
mice, when challenged with BCG, produce higher levels
of TNF-a with concomitant accelerated clearance of
mycobacteria [33]. These observations were further vali-
dated by clinical studies, showing higher levels of IL-10
production in patients with active pulmonary TB
[34,35]. Moreover, overproduction of IL-10 by T cells
was shown to be related to suppressed immunity and
increased susceptibility to mycobacteria infection [36].
Radix Paeoniae Rubra (RPR, Chishao), the dried root
of Paeonia lactiflora Pallas or Paeonia veitchii Lunch
[37], has been widely used by Chinese medicine practi-
tioners to treat cardiovascular, inflammation and female
reproductive diseases [38]. Based on the principle of
Chinese medicine, historical literatures described RPR
with the functions of tonifying blood, cooling blood,
cleansing heat, and invigorating blood circulation. It is
often used as an “Assistant” herb to counteract or ame-
liorate the undesirable side effects of the “King” herbs
[37]. In contemporary literatures, RPR is used for the
treatment of the following diseases: seasonal febrile dis-
eases with eruptions, bleeding, menstrual disorders,
trauma, skin infection and conjunctivitis as well as pain
over the chest, hypochondrium and abdomen [39]. RPR
is also used in some herbal formulae to treat TB
patients [40]. RPR has protective effects on lung injury
through the induction of heme oxygenase-1 (HO-1) and
suppression of nitric oxide (NO) in rats [41,42]. In a
mouse model, the extracts obtained from RPR and
Astragalus membranaceus protected the liver from
BCG/endotoxin-induced injury. These protective effects
were associated with downregulation of pro-inflamma-
tory cytokines [43]. While some studies on the biological
effects and chemical constituents of RPR have been
reported [38], the immunoregulatory effects of RPR and
their detailed mechanisms of action at cellular signaling
levels are yet to be investigated, especially the interac-
tion of BCG with human blood macrophages.
In the present study, an active fraction, namely RPR-
EA-S1, was isolated from the crude extracts of RPR
using a bioactivity-guided fractionation scheme. The
chemical profile of RPR-EA-S1 was analyzed by high
performance liquid chromatography (HPLC) and gas
chromatography mass spectrometry (GC-MS). The reg-
ulatory effects of crude RPR extract and its fraction
RPR-EA-S1 on BCG-induced cytokine and chemokine
expression in human PBMac were examined. The
underlying mechanisms of the inhibitory effects of
RPR-EA-S1 on BCG-induced IL-10 expression were
delineated.
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Methods
Plant material
Radix Paeoniae Rubra was obtained from PuraPharm
International Ltd. (Hong Kong, China). The raw mate-
rial of the herb was authenticated by PuraPharm
Corporation (Guangxi, China) according to the method
in the Pharmacopoeia of the People’s Republic of China
2005 [44] which states that the RPR sample should not
contain less than 1.8% of paeoniflorin, calculated with
reference to the dried substance. The Radix Paeoniae
Rubra used in our study contained more than 4% of
paeoniflorin.
Preparation of the crude extract from Radix Paeoniae
Rubra
The procedures for raw herb extraction and fractiona-
tion were shown in Figure 1. Briefly, the herbs (300 g)
were ground into powder and extracted with eight folds
(volume) of Milli Q water (Sartorius, Germany) under
reflux for one hour. The extraction was repeated for
three times. The resulting extracts were combined and
concentrated at 70°C under reduced pressure until the
density reached 1.28 g/mL. Then the paste collected was
precipitated with five folds (volume) of ethanol (EtOH).
After filtration, the supernatant was evaporated to dry-
ness in an evaporator (Rotavapor R-200, BUCHI, Swit-
zerland), yielding crude RPR extract (81 g). The extract
was then dissolved in methanol (MeOH) and partitioned
with an equal volume of hexane (n-C6H14) for three
times. The MeOH extract was dried and re-dissolved in
water and then partitioned sequentially with an equal
volume of ethyl acetate (EtOAc) and n-butanol
(n-BuOH) for four times. Four fractions were obtained,
namely RPR-H, RPR-EA (10 g), RPR-Bu and RPR-W.
According to a bioassay guided scheme, the fraction
RPR-EA with the most potent activity on IL-10 suppres-
sion was selected and further separated by silica gel col-
umn chromatography (Merck, Germany). After loading
Figure 1 Extraction and separation scheme of RPR-EA-S1 from RPR. RPR powder was extracted by Milli Q water under reflux and the
extract was precipitated with EtOH. The resulting supernatant was concentrated and partitioned sequentially with n-C6H14, EtOAc and n-BuOH.
The extracts were tested for their inhibitory effects on IL-10 production in primary human blood macrophages stimulated by BCG. The bioactive
RPR-EA was further separated by silica gel column chromatography. RPR-EA-S1 fraction was selected by bioactivity assay and analyzed by HPLC
and GC-MS.
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the sample, the column was washed sequentially with a
series of solvents: 50% n-C6H14 in EtOAc, 100% EtOAc,
EtOAc combined with 10%, 30%, 50% or 70% of MeOH
and finally 100% MeOH. These serial washings yielded
seven fractions: RPR-EA-S1 (0.78 g), RPR-EA-S2, RPR-
EA-S3, RPR-EA-S4, RPR-EA-S5, RPR-EA-S6 and RPR-
EA-S7.
Chemicals and antibodies
All the chemical solvents such as EtOH, MeOH,
n-BuOH, EtOAc and n-C6H14 were purchased from
Merck (Germany). Antibodies against NF-B1 p50,
actin, IBa and Lamin B were purchased from Santa
Cruz Biotechnology (USA). Antibodies against phos-
pho-ERK1/2, phospho-p38, phospho-Akt and phospho-
GSK3b as well as antibodies against total ERK1/2, p38,
Akt and GSK3b were purchased from Cell Signaling
Technology (USA). Anti-rabbit IgG HRP-conjugated
secondary antibodies were purchased from BD
Biosciences (USA). Anti-goat IgG HRP-conjugated
secondary antibodies were purchased from ZYMED
Laboratory (USA).
Bacillus Calmette-Guerin
Bacillus Calmette-Guerin (BCG) is a live freeze-dried
vaccine made from an attenuated strain of Mycobacter-
ium bovis, Danish strain 1331. The vaccine, which con-
tains no virulent Mtb, was purchased from Statens
Serum Institut (Denmark).
Isolation of primary human peripheral blood
macrophages
Using Ficoll-Paque (GE Healthcare, USA) density gradient
centrifugation as previously described [3,29], we isolated
primary human peripheral blood macrophages (PBMac)
from buffy coats of healthy blood donors obtained from
the Hong Kong Red Cross Blood Transfusion Service.
Briefly, the fresh blood samples were centrifuged at 3000
rpm (1811g, Eppendorf AG, Germany) for 20 minutes and
separated into plasma and blood cell layers. The plasma
layer was carefully removed and heat-inactivated for
30 minutes at 56°C in water bath, followed by chilling on
ice for ten minutes. It was centrifuged at 4000 rpm (3220g,
Eppendorf AG, Germany) for ten minutes to remove the
precipitates. The clear supernatant was then filtered
through 0.45 μm membranes and later used as the autolo-
gous plasma added to culture macrophages. The blood
cell layer was diluted with an equal volume of phosphate
buffered saline (PBS) at a ratio of 1:1 and then slowly over-
laid over the Ficoll and centrifuged for 20 minutes at 2300
rpm (1065g, Eppendorf AG, Germany). The white blood
cell layer was removed and washed with RPMI 1640 (Invi-
trogen, USA) for three times and the supernatant was
clear after washes. The cell pellet was re-suspended with
RPMI medium containing 5% autologous plasma and 1%
penicillin/streptomycin and plated onto a tissue culture
Petri dish. The dish was incubated at 37°C in a humidified
atmosphere with 5% CO2 for one hour to allow monocytes
to adhere. The unattached cells were washed away by
warm RPMI medium and the adherent monocytes were
incubated at 37°C overnight. Subsequently, cold RPMI
medium with 5 mM ethylenediaminetetraacetic acid
(EDTA) was used to wash and detach the monocytes,
which were finally seeded onto the tissue culture plates in
RPMI medium supplemented with 5% autologous plasma
and 1% penicillin/streptomycin. After 14 days of culturing,
with replenishment of medium every three to four days,
the monocytes derived macrophages were ready for
treatment.
Total RNA extraction and reverse transcription
Total RNA was extracted with TRIzol Reagent (Invitro-
gen, USA). SuperScript II transcriptase (Invitrogen,
USA) was used to synthesize cDNA from the total RNA
according to the manufacturer’s instructions. The cDNA
samples were kept at -20°C until use.
Quantitative real-time PCR
The expression levels of IL-6, IL-8, IL-10 and TNF-a
mRNA were determined with quantitative real-time
PCR (q-PCR) on an ABI 7500 system using TaqMan
(Applied Biosystems, USA). The relative quantification
method was used to calculate the mRNA expression
levels [45]. Briefly, we applied a 20 μL reaction system
containing the sample cDNA, TaqMan 2× Master Mix,
TaqMan probes for target genes (gene-specific Assays-
on-Demand reagent kits, Applied Biosystems, USA) and
TaqMan probe for 18 s rRNA as the internal control.
Each sample was run in duplicates. The threshold cycle
number (Ct) of the target gene was normalized to the
Ct of 18 S rRNA for each sample (-ΔCt). The -ΔCt
value of the mock-treated sample was subtracted from
the -ΔCT value of other samples, yielding -ΔΔCt. And
the value of 2-ΔΔCt refers to the fold change of target
gene’s mRNA expression level compared to that of the
corresponding mock-treated sample.
Enzyme-linked immunosorbent assay (ELISA)
To study the RPR’s differential effects on cytokines
inducible by BCG, we applied ELISA to measure the
amounts of IL-6, IL-8, IL-10 and TNF-a in the cell cul-
ture supernatants. Briefly, macrophages (PBMac) derived
from human primary monocytes were seeded onto a
24-well plate at a concentration of 106/mL. After pre-
treatment of PBMac with the RPR extract or its desig-
nated partially purified fractions for 16 hours, BCG
(MOI = 1) was added to the cell cultures. After
24 hours of incubation, the supernatants were collected
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and the concentrations of cytokines were measured with
ELISA according to the manufacturer’s instructions
(R&D Systems, USA).
Western blot analysis
Cytoplasmic proteins and nuclear proteins were
extracted separately with buffer A and buffer C as pre-
viously described [46] with modifications. Cells were
washed twice with cold PBS and lysed on ice with buffer
A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 2 μg/mL
aprotinin, 1 mM sodium orthovanadate, 2 μg/mL pep-
statin, 2 μg/mL leupeptin and 50 mM sodium fluoride)
for 15 minutes. Then 10% NP-40 was added to the cells
at a final concentration of 0.625%, followed by several
seconds of vortexing. The cells were then removed with
a clean scraper. The lysate was then centrifuged at
15000g for 30 seconds. The supernatant containing cyto-
plasmic proteins was stored at -70°C until use. The pel-
let was washed gently with buffer A and centrifuged
again (15000g, Eppendorf AG, Germany) to obtain a pel-
let by discarding the supernatant. The nuclear proteins
were extracted by re-suspending the pellet in buffer C
(20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, 1 mM PMSF, 1 μg/mL apro-
tinin, 1 mM sodium orthovanadate, 2 μg/mL pepstatin,
2 μg/mL leupeptin and 50 mM sodium fluoride). The
sample was lysed on ice for 15 minutes with vortexing
every five minutes. The nuclear extract was centrifuged
(15000g, Eppendorf AG, Germany) at 4°C for five min-
utes and the supernatant was stored at -70°C until use.
Protein concentrations were quantified with the Bio-
Rad protein assay kit (USA). Then an equal amount of
proteins (30 μg of cytoplasmic or 4 μg of nuclear pro-
teins) was separated by 10% SDS-PAGE and transferred
to a nitrocellulose membrane. After three hours of incu-
bation with 1% BSA in tris-buffered saline Tween-20
(TBST), the membrane was incubated with a specific
antibody (1:1000 dilution) to the protein of interest for
overnight at 4°C. Then the membrane was washed with
TBST and incubated with the corresponding secondary
antibody (1:4000 dilution) for one hour at room tempera-
ture. After five times of washes, the bands in the mem-
brane were detected with a GE Healthcare Enhanced
Chemiluminescence System (USA) according to the
manufacturer’s instructions. ImageJ (National Institutes
of Health, USA) was used to quantify the levels of pro-
teins captured in the laser densitometry results.
MTT assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assays were used to test the cytotoxicity
of the RPR extract and its partially purified fractions on
the cells. PBMac were seeded at a concentration of
106/mL in a 24-well plate. After 48 hours of treatment
with the RPR extract or its designated fractions, the
cells were incubated with RPMI 1640 medium contain-
ing 0.5 mg/mL MTT (Invitrogen, USA) for one hour.
Then the cell culture medium was removed and isopro-
panol (IPP) was added to the wells and incubated at
room temperature for ten minutes. Absorbance values
of the culture medium at 570 nm were measured with a
microplate reader (Bio-Rad, USA).
High performance liquid chromatography (HPLC) analysis
of the extracts
The RPR extract and its fractions were dissolved in
HPLC grade MeOH (Merck, Germany) before analysis.
HPLC was performed with an Agilent 1200 liquid chro-
matography system (Agilent, USA) equipped with a
reverse-phase HPLC column (Lichrospher 100, RP C18
EC 5 μm, 250 × 4.6 mm ID) described in our previous
reports [47,48]. A gradient elution from 10% acetonitrile
(CH3CN) to 90% CH3CN at a flow rate of 1 mL/min
was used to separate the peaks which were detected at
210 nm with an Agilent 1200 series (Agilent, USA), a
fast scanning photodiode array detector.
Gas chromatography mass spectrometry
Before GC-MS analysis, the RPR extracts first underwent
silylation. Briefly, 100 μL RPR-EA-S1 in CH3CN was
mixed with 50 μL of pyridine and 50 μL of the derivatiz-
ing agent BSTFA [N, O-bis(trimethylsilyl)trifloroaceta-
mide] in a 1 mL reaction vial (Alltech, USA). After
incubation for two hours at 70°C, bis-trimethyl silyl tri-
fluoroacetamide (BSTFA) replaced the labile hydrogen
atom with a -Si(CH3)3 group on a wide range of polar
compounds. Then the resulting mixture was analyzed by
GC-MS (GC: 7890A, MS: 5975C, Agilent, USA) equipped
with a HP-5MS column (Agilent, USA) (30 m × 250 μ m
× 0.25 μ m). The sample (1 μl) was injected to the col-
umn. Helium was used as the carrier gas at a flow rate of
1 mL/min. The oven temperature was started at 70°C for
one minute, and then increased to 180°C at a rate of
10°C/min; after two minutes’ holding, increased to 280°C
at a rate of 10°C/min and held for three minutes. The
interface temperature was 250°C, ion source temperature
was 230°C, and electron impact ionization (EI) was at
200 eV. Mass spectra were analyzed in the range of
50-700 atom mass units (amu) for a run time of 22 min-
utes. The G1701EA Chemstation (Agilent, USA) was
used to perform the MS data analysis. The peaks of the
eluants with more than 90% similarity to the compounds
listed in the NIST GC-MS library were selected.
Statistical analysis
All data were presented as the mean ± standard devia-
tion (SD). Data were analyzed with the SPSS statistical
Wang et al. Chinese Medicine 2011, 6:14
http://www.cmjournal.org/content/6/1/14
Page 5 of 14
package (version 11.5.0, SPSS Inc, USA). The statistical
differences in the respective protein levels and mRNA
levels among treatments were tested by one-way
ANOVA followed by an Honestly Significant Difference
(HSD) post-hoc Tukey test. P value of less than 0.05 is
considered statistically significant.
Results
Extraction and bioassay guided fractionation of RPR
Using solvent partitioning extraction, we obtained RPR-
H, RPR-EA, RPR-Bu and RPR-W. MTT assays showed
that all four fractions were not toxic to PBMac at 50
μg/mL (Additional file 1). Therefore, each fraction at 50
μg/mL was tested for their inhibitory effects on BCG
(MOI = 1, MOI: multiplicity of infection) induced IL-10
production in PBMac. We reported previously that 24
hours of BCG stimulation was an optimal time point
for studying BCG-induced IL-10 expression [30]. The
present study used the same time point. The ELISA
assays found that PBMac pretreated with RPR-EA
showed 68% reduction in IL-10 production induced by
BCG while RPR-H, RPR-Bu and RPR-W did not show
any inhibitory effect (Figure 2A). Using silica gel col-
umn chromatography, we further separated RPR-EA,
the most potent fraction, into seven sub-fractions,
namely RPR-EA-S1 to RPR-EA-S7 (Figure 1). Additional
MTT assays demonstrated that none of them was toxic
to PBMac at 50 μg/mL (Additional file 2). The ELISA
results found that pretreatment of PBMac with fractions
RPR-EA-S1, RPR-EA-S2 and RPR-EA-S6 (20 μg/mL)
showed 66%, 40% and 62% reduction of BCG-induced
IL-10 production respectively whereas the remaining
fractions did not have inhibitory effects (Figure 2B).
RPR-EA-S1, the most biologically active fraction, was
selected for further analysis and investigation. The che-
mical profiles of the crude RPR extract as well as RPR-
EA and RPR-EA-S1 were analyzed with reverse phase
HPLC (Additional file 3).
Differential effects of RPR extracts on BCG-induced
cytokine and chemokine expression
Since cytokines and chemokines secreted by macro-
phages play a critical role in the host immune responses
against mycobacteria, we examined the RPR’s regulatory
effects on BCG-induced IL-6, IL-8, IL-10 and TNF-a
expression in PBMac. Pretreatment of the immune cells
with RPR extract had no effect on BCG-induced IL-6 or
TNF-a expression; however, it significantly reduced the
production of IL-10 and increased that of IL-8 at both
mRNA and protein levels (Figure 3). The differential
effects of RPR on BCG-induced cytokine and chemokine
expression were further confirmed with three batches of
RPR extracts (Additional file 4).
Differential effects of RPR-EA-S1 on BCG-induced cytokine
and chemokine expression
To investigate whether the partially purified fraction
RPR-EA-S1 contained the immuno-regulatory activity
derived from the crude RPR extract, we performed
ELISA on IL-6, IL-8, IL-10 and TNF-a. RPR-EA-S1’s
regulatory patterns on the four cytokines or chemo-
kines were similar to those of RPR crude extracts
(Figure 3 and 4). RPR-EA-S1 inhibited IL-10 and
enhanced IL-8 expression, while had no effect on IL-6
and TNF-a expression in the BCG-induced PBMac.
When compared to the crude RPR extract (Figure 3B),
RPR-EA-S1 was more effective in terms of the levels of
IL-10 inhibition and IL-8 induction in BCG-stimulated
PBMac (Figure 4).
Figure 2 Bioassay guided fractionation of RPR. PBMac (5 × 105)
were pretreated with 0.05% DMSO or the indicated RPR fractions
(A) or RPR-EA subfractions (B) overnight and then stimulated with
BCG (MOI = 1). Culture supernatants were collected after 24 hours.
The levels of IL-10 in the supernatants were measured by ELISA. The
IL-10 concentration in the supernatant of DMSO + BCG sample was
set as 100%, and the rest were compared to it to obtain a
percentage value. Results are shown as mean ± SD from
independent experiments on PBMac obtained from three different
healthy donors. *P < 0.05, **P < 0.001 compared to the DMSO +
BCG sample (one-way ANOVA, Tukey’s test).
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Figure 3 Effects of RPR crude extract on the expression levels of cytokines in BCG-stimulated PBMac. PBMac (5 × 105) were
pretreated with 0.1% DMSO or 100 μg/mL RPR extract overnight and then stimulated with BCG (MOI = 1). (A) Total mRNA was extracted
after 3 hours for cDNA synthesis. The levels of mRNA were determined by q-PCR. The mRNA level of the DMSO + BCG sample was set as
100%, and the rest were compared to the DMSO + BCG sample to obtain a percentage value. (B) Culture supernatants were collected after
24 hours. The levels of IL-6, IL-8, IL-10 and TNF-a in the supernatants were measured by ELISA. The individual cytokine level in the
supernatant of the DMSO + BCG sample was set as 100%, and the rest were compared to it to obtain a percentage value. Results are
shown as mean ± SD from independent experiments on PBMac obtained from three (A) or six (B) different healthy donors. *P < 0.05, **P <
0.001 compared to the DMSO + BCG sample (one-way ANOVA, Tukey’s test).
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Moreover, the inhibitory effect of RPR-EA-S1 on
BCG-induced IL-10 production was in a dose-dependent
manner between 5 μg/mL and 50 μg/mL both at the
protein and mRNA levels (Figure 5A and 5B). The regu-
latory effects were significant even at a low concentra-
tion of 5 μg/mL.
The IL-10 mRNA expression levels were studied over
a time course of 24 hours. Figure 5C shows that the
BCG-induced IL-10 expression reached the peak level at
three hours before declining to the basal level at
24 hours; however, pretreatment of the cells with RPR-
EA-S1 inhibited BCG-induced IL-10 mRNA expression
throughout the time course.
RPR-EA-S1, a fraction of RPR, demonstrated differen-
tial effects on cytokine and chemokine expression in
BCG-stimulated PBMac, enhanced BCG-induced IL-8
production and inhibited IL-10 production in a dose
and time-dependent manner.
Mechanisms underlying RPR-EA-S1 inhibition of IL-10
expression in BCG-stimulated blood macrophages
After confirming the inhibitory effect of RPR-EA-S1 on
BCG-induced IL-10 expression, we investigated the
mechanisms underlying the decrease of IL-10 expres-
sion. Mitogen-activated protein kinases (MAPK) are
involved in IL-10 regulation [3,25]. BCG increases the
phosphorylation of ERK1/2 and p38 [3]. This study
showed that pretreatment with RPR-EA-S1 did not
affect the phosphorylation levels of ERK1/2 and p38
induced by BCG stimulation (Figure 6A and 6B). Since
Figure 4 Effects of RPR-EA-S1 on the production of different cytokines or chemokines in BCG-stimulated PBMac. PBMac (5 × 105) were
pretreated with 0.01% DMSO or 20 μg/mL of RPR-EA-S1 overnight and then stimulated with BCG (MOI = 1). Supernatants were collected after
24 hours. The levels of IL-6, IL-8, IL-10 and TNF-a in the supernatants were measured by ELISA. The individual cytokine level in the supernatant
of DMSO + BCG sample was set as 100%, and the rest were compared to it to obtain a percentage value. Results are shown as mean ± SD from
independent experiments on PBMac obtained from four different healthy donors. **P < 0.001 compared to the DMSO + BCG sample (one-way
ANOVA, Tukey’s test).
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Akt/GSK3b is a key pathway involved in BCG-induced
IL-10 expression [30], we examined the effect of RPR-
EA-S1 on this pathway. The study found that the phos-
phorylation of Akt or GSK3b, inducible by BCG, was
not affected by pretreatment of the cells with RPR-EA-
S1 (Figure 6A and 6B). Neither MAPK kinases nor the
Akt/GSK3b pathway was involved in the inhibitory
effects of RPR on BCG-induced IL-10 production.
Downstream of these kinases, specific transcriptional
factors may also affect IL-10 expression. Our previous
study demonstrated a correlation between the transloca-
tion of NF-B1 p50 into the nucleus and the induction
of IL-10 by BCG [30]. In the present study, Western
blotting was performed to examine the translocation of
NF-B1 p50 to the nucleus. The results confirmed the
induced translocation of NF-B1 p50 by BCG while
RPR-EA-S1 pretreatment of the cells reduced such
effects (Figure 6C and 6D). Similarly, the IBa was
degraded after BCG stimulation while pretreatment of
the cells with RPR-EA-S1 significantly inhibited this
degradation (Figure 6C and 6D).
Suppression of BCG-induced IL-10 by RPR-EA-S1
were achieved through suppression of IBa degradation
and inhibition of NF-B1 p50 translocation to the
nucleus (Figure 7).
GC-MS analysis of the chemical constituents of RPR-EA-S1
To further investigate the chemical components of RPR-
EA-S1, we performed GC-MS analysis (Additional files
5 and 6). The mass spectra generated from the extracts
were compared to the compounds in NIST GC-MS
library. Two major groups of compounds were found in
RPR-EA-S1, namely phenols (including hydroquinone,
4-hydroxybenzoic acid and ferulic acid) and fatty acids
(including unsaturated and saturated fatty acids).
Discussion
Recent resurgence of mycobacterial infection is in part
due to the spread of AIDS in developing countries. Com-
bined administration of specific anti-mycobacterial drugs
is the current TB treatment recommended by the World
Health Organization [49]. With increases in multidrug-
resistant-TB (MDR-TB) and extensively drug-resistant
(XDR)-TB strains, the need to develop new anti-Mtb
drugs is urgent and immuno-modulatory agents have
been considered to enhance TB treatment [50].
We demonstrated that the crude RPR extract and its
fraction RPR-EA-S1 augmented BCG-induced IL-8
expression (Figure 3 and 4). Decreased IL-8 secretion
was observed in HIV-infected patients with miliary TB
[20]. In vivo studies showed that anti-IL-8 antibody
inhibited the formation of granuloma in rabbits [51],
Figure 5 Dose-dependent and time course effects of RPR-EA-
S1 on the production of IL-10 in BCG-stimulated PBMac.
PBMac (5 × 105) were pretreated with 0.05% DMSO or different
dose of RPR-EA-S1 overnight and then stimulated with BCG (MOI
= 1). (A) Supernatants were collected after 24 hours. The levels of
IL-10 in the supernatants were measured by ELISA. (B) Total mRNA
was extracted after 3 hours for cDNA synthesis. The levels of
mRNA were determined by q-PCR. The mRNA or protein
expression levels of DMSO + BCG sample were set as 100%, and
the rest were compared to DMSO + BCG to obtain a percentage
value. (C) PBMac (5 × 105) were pretreated with 0.01% DMSO or
20 μg/mL of RPR-EA-S1 overnight and then stimulated with BCG
(MOI = 1) for 0, 1, 3, 6, 12 and 24 hours. Total mRNA was used to
synthesize cDNA. The levels of IL-10 mRNA were determined by q-
PCR. Results are shown as mean ± SD from independent
experiments on PBMac obtained from three different healthy
donors. *P < 0.05, **P < 0.0001 compared to the DMSO + BCG
sample (one-way ANOVA, Tukey’s test for Figures 5A and B, t-test
for Figure 5C).
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suggesting a significant role for IL-8 in controlling Mtb
infection by the host immunity. Recent studies showed
that IL-8 attracted neutrophils and T lymphocytes to
the infection sites for the formation of granuloma and
augmentation of cell mediated immunity [52]. IL-8 also
activated neutrophils to exhibit bactericidal responses
[53]. Therefore, the enhanced IL-8 induction by RPR
may be beneficial to the initiation of host immune
responses against Mtb and the subsequent formation of
the granuloma in human [51].
We also showed that crude RPR extract and its
fraction RPR-EA-S1 can inhibit BCG-induced IL-10
expression (Figure 3, 4, 5). IL-10 is a well known anti-
inflammatory cytokine produced by macrophages and T
cells during Mtb infection [3]. The relationship between
IL-10 production and TB progression was well observed
in both animal and human studies [32,33,36]. Recent
studies revealed that Mtb utilized IL-10 to evade the
host immunity. Firstly, induction of IL-10 inhibited the
production of bactericidal molecules including NO and
RNIs by macrophages [54]. Secondly, IL-10 suppressed
pro-inflammatory cytokines such as IL-12, TNF-a and
IFN-g, resulting in reduced Th1 cell immunity, CD4+
and CD8+ lytic activity, as well as delayed macrophage
activation [31]. Thirdly, IL-10 suppressed antigen pre-
sentation by down-regulating MHC and other co-stimu-
latory molecules on the cell surface of monocytes/
macrophages [31]. We recently showed that this effect
was due to IL-10 activation of STAT3 to suppress
cathepsin S expression [29]. Fourthly, IL-10 inhibited
TNF-a activity by down-regulating TNF-a expression
and inducing soluble TNF receptor 2, leading to
reduced apoptosis and increased pathogen survival [55].
Fifthly, macrophage-derived IL-10 triggered alternative
macrophage activation in Mtb infection, in which argi-
nase-1 gene expression was strikingly enhanced. In turn,
Figure 6 Effects of RPR-EA-S1 on signaling kinases and NF-B expression in BCG-stimulated PBMac. PBMac (2 × 106) were pretreated
with 0.01% DMSO or 20 μg/mL of RPR-EA-S1 overnight and then stimulated with BCG (MOI = 1) for 30 minutes. Cytoplasmic proteins and
nuclear proteins were extracted separately. (A) and (C): The levels of phospho-MAPK, phospho-GSK and phospho-Akt, as well as NF-B1 p50 and
IBa were analyzed with Western blot. The figures showed one set of representative results from independent experiments on PBMac obtained
from three different healthy donors. (B) and (D): Quantification of the Western blot was measured by laser densitometry. Intensities of phospho-
MAPK, phospho-GSK, phospho-Akt, NF-B1 p50 and IBa were normalized to the corresponding MAPK, GSK, Akt, Lamin B and Actin,
respectively. Results are shown as mean ± SD from independent experiments on PBMac obtained from three different healthy donors. *P < 0.05
compared to the DMSO + BCG sample (one-way ANOVA, Tukey’s test).
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arginase-1 negatively regulated microbicidal mechanisms
in macrophages and promotes Mtb recrudescence [56].
The inhibitory effects of RPR on BCG-induced IL-10
production may have a beneficial effect on the host for
the reversal of the immunosuppressive effects of IL-10
thereby speeding up the killing of Mtb.
Multiple pathways are involved in the regulation of
BCG-induced IL-10 expression, including ERK1/2, p38
and PI3K/GSK3 [3,30]. In the present study, RPR
showed no effect on either of these pathways (Figure 6A
and 6B); however, RPR inhibited NF-B1 p50 transloca-
tion to the nucleus (Figure 6C and 6D). NF-B plays a
role in promoting the production of cytokines [57].
NF-B is a family of transcriptional factors, including
RelA (p65), NF-B1 (p50 and p105), NF-B2 (p52 and
p100), c-Rel and RelB, bound with an inhibitory protein
named IB in the cytoplasm. After stimulation, IB
undergoes phosphorylation and degradation, resulting in
the release of NF-B for translocation to the nucleus,
leading to transcription of their regulated target genes
[58]. Among members of the NF-B family, NF-B1
p50/p50 homodimer was involved in IL-10 transcription
[59]. In murine macrophages, NF-B1 p50/p50 homodi-
mer activated transcription of IL-10 together with the
CREB protein [59]. Macrophages from NF-B1 p50
knock-out mice expressed less IL-10 compared to nor-
mal mice upon lipopolysaccharide challenge [59]. The
present study shows that RPR-EA-S1 significantly
reduced the degradation of IBa in the cytoplasm and
inhibited the translocation of NF-B1 p50 to the
nucleus in BCG-induced human blood macrophages
(Figure 6). Therefore, the inhibition of IL-10 by RPR-
EA-S1 may be mediated by the effects of its constituents
on NF-B1 translocation (Figure 7).
While NF-B pathway also regulates IL-6, IL-8 and
TNF-a, previous studies indicated that the transcrip-
tions of IL-6, IL-8 and TNF-a were not mainly regu-
lated by NF-B1 p50 homodimer [59-61]. Instead,
silencing of NF-B p65 rather than p50 gene was effec-
tive in down-regulating TNF-a induced IL-6 and IL-8
mRNA synthesis [61]. In luciferase activity assays of the
TNF-a promoter, p50 plays little role in driving the
transcription, while c-Rel and p65 plays dominant roles
in inducing the transcription [60]. Therefore, the inhibi-
tion of NF-B1 p50 translocation to the nucleus cannot
affect BCG-induced IL-6, IL-8 and TNF-a expression.
Moreover, the transcriptional regulation of cytokines
involved multiple transcriptional factors and was indu-
cer-dependent [62-64]. For example, respiratory syncy-
tial virus (RSV) may increase IL-8 production in the
airway epithelium partly via the activation of transcrip-
tion factors including NF-B and NF-IL-6 [65] whereas
AP-1 and NF-B are essential transcription factors for
IL-1b-induced IL-8 gene expression [66]. In BCG stimu-
lated macrophages, it is possible that in addition to
NF-B, multiple transcriptional factors may contribute
to the expression of IL-6, IL-8 and TNF-a. The inhibi-
tion of NF-B pathway may be compensated by other
transcriptional factors. This may also explain why the
BCG-induced IL-6, IL-8 and TNF-a expression were
not inhibited by RPR-EA-S1.
The major groups of compounds in the RPR-EA-S1
fraction were phenols and fatty acids. Both phenols and
fatty acids are biologically active compounds commonly
present in the genus of Paeonia [67-69]. For example,
ferulic acid, one of the phenols isolated from Paeonia,
scavenges free reactive radicals as determined by DPPH
(1, 1-Diphenyl-2-picrylhydrazyl) assay and inhibits lipid
peroxidation and protects DNA from oxidative damage
[69]. Phenylacetic acid, plant hormone that had been
used to treat type II hyperammonemia [70], was also
detected in RPR-EA-S1. Our future studies will isolate
the compounds responsible for the immuno-regulatory
effects of RPR-EA-S1.
Figure 7 Mechanisms underlying the immunomodulation effects
of RPR-EA-S1. In BCG-stimulated macrophages, RPR-EA-S1 can
specifically inhibit IL-10 production and yet enhance IL-8 expression.
RPR-EA-S1 did not affect the phosphorylation of cellular protein kinases
including ERK, p38, Akt and GSK3b. Its inhibitory effects in BCG-activated
IL-10 expression may be, at least in part, through the suppression of the
degradation of IBa in the cytoplasm and thus inhibited the
translocation of transcription factor NF-B1 p50 to the nucleus.
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Conclusion
RPR crude extracts and its fraction RPR-EA-S1 specifically
inhibited anti-inflammatory cytokine IL-10 and enhanced
pro-inflammatory chemokine IL-8 expression in BCG-
activated PBMac. The inhibitory effects of RPR-EA-S1 on
IL-10 expression in BCG-activated PBMac may be due to
the reduced nuclear translocation of NF-B1 p50.
Additional material
Additional file 1: Effects of different RPR fractions on the cell
viability of human PBMac. PBMac (5 × 105) were treated with different
doses of RPR fractions for 48 hours. The cell viability was tested by MTT
assay. Results are shown as mean ± SD from independent experiments
on PBMac obtained from three different healthy donors. *P < 0.05
compared to the DMSO treated sample (one-way ANOVA, Tukey’s test).
Additional file 2: Effects of different RPR-EA subfractions on the cell
viability of human PBMac. PBMac (5 × 105) were treated with different
doses of extracts for 48 hours. The cell viability was tested by MTT assay.
Results are shown as mean ± SD from independent experiments on
PBMac obtained from three different healthy donors.
Additional file 3: HPLC chromatogram of RPR, RPR-EA and RPR-EA-
S1. The HPLC was performed by using a reverse-phase HPLC column
(Lichrospher 100 RP C18 EC 5 μm, 250 × 4.6 mm ID) and the detection
wavelength (WL) was set at 210 nm. The flow rate was 1 mL/min. The
solvents used in gradient elution were (A) water and (B) acetonitrile
(CH3CN). The program was set as follows.
Time (Minutes) % Solvent (A) % Solvent (B)
0 90 10
10 60 40 Gradient
15 10 90 Gradient
17 10 90 Isocratic
20 90 10 Gradient
25 90 10 Isocratic
Additional file 4: Effects of three different batches of RPR extracts
on cytokine expression in BCG-stimulated PBMac. PBMac (5 × 105)
were pretreated with 0.1% DMSO or 100 μg/mL of different batches of
RPR extracts (R1, R2 and R3) overnight and then stimulated with BCG
(MOI = 1). Supernatants were collected after 24 hours. The levels of IL-6,
IL-8, IL-10 and TNF-a in the supernatants were measured by ELISA. The
individual cytokine level in the supernatant of the DMSO + BCG sample
was set as 100%, and the rest were compared to it to obtain a
percentage value. Results are shown as mean ± SD from independent
experiments on PBMac obtained from three different healthy donors.
*p < 0.05, **p < 0.001 compared to the DMSO + BCG sample (one-way
ANOVA, Tukey’s test).
Additional file 5: total ion chromatogram of RPR-EA-S1. After
reaction with derivatizing agent BSTFA [N, O-bis (trimethylsilyl)
trifloroacetamide], RPR-EA-S1 was analyzed by GC-MS equipped with a
HP-5MS column (30 m × 250 mm × 0.25 mm). The spectra of the peaks
were compared to the spectra listed in the NIST GC-MS library. Only
peaks with >90% similarity to the compounds in database were listed in
Additional file 6.
Additional file 6: Compounds detected in RPR-EA-S1 using GC-MS.
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amu: atom mass units; BCG: Bacillus Calmette-Guerin; BSTFA: bis-trimethyl
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isopropanol; MAPK: mitogen-activated protein kinases; MDR-TB: multidrug-
resistant TB; MeOH: methanol; MOI: multiplicity of infection; Mtb:
Mycobacterium tuberculosis; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-
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p50: nuclear factor-κB1 p50; NO: nitric oxide; PBMac: peripheral blood
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quantitative real-time PCR; RNIs: reactive nitrogen intermediates; ROIs:
reactive oxygen intermediates; RPR: Radix Paeoniae Rubra; RSV: respiratory
syncytial virus; SD: standard deviation; TB: tuberculosis; TBST: tris-buffered
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